RudĂ , Roberta http://orcid.org/0000-0001-9134-1537
Horbinski, Craig http://orcid.org/0000-0001-8340-9992
van den Bent, Martin http://orcid.org/0000-0001-5710-5127
Preusser, Matthias http://orcid.org/0000-0003-3541-2315
Soffietti, Riccardo http://orcid.org/0000-0002-9204-7038
Article History
Accepted: 26 April 2024
First Online: 17 May 2024
Competing interests
: R.R. has received honoraria for lectures from UCB, Servier, Genenta, Novocure and Curevac. M.v.d.B. reports consulting for Boehringer Ingelheim, F. Hoffman-La Roche, Fore Biotherapeutics, Genenta, Incyte Corporation, AnHeart therapeutics, Mundipharma, SymBio Pharma and Servier Affaires Medicales. M.P. has received honoraria for lectures, consultation or advisory board participation from Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dome, Tocagen, Adastra, Gan & Lee Pharmaceuticals, Janssen, Servier, Miltenyi, Böhringer Ingelheim and Telix, Medscape. R.S. has received honoraria for lectures, consultation or advisory board participation from Celldex Therapeutics, Mundipharma, Puma Technology, Astra Zeneca, Servier and Seagen. C.H. declares no competing interests.